Oncology, Diabetes Dominate Korean Out-Licensing But Deals And Value Decline

Scrip takes a look at how the South Korean pharma/biotech industry's cross-border deals over the past few years compare with...

More From BioPortfolio on "Oncology, Diabetes Dominate Korean Out-Licensing But Deals And Value Decline"